About Speciality Medicines
Speciality Medicines Limited, incorporated in 2021, is engaged in the marketing and distribution of speciality pharmaceutical formulations. The company focuses on high-value oral and injectable medicines used to treat complex and chronic medical conditions. These medicines are supplied to both domestic and international markets. The company offers a diverse portfolio of finished pharmaceutical formulations available in multiple dosage forms such as tablets, capsules, creams, syrups, eye drops, gels, injections, inhalers, nasal sprays, ointments, infusions, oral solutions, sachets, suspensions, and ophthalmic solutions. This wide range allows the company to cater to different therapeutic needs and healthcare markets. Speciality Medicines operates through two main business models. The first is contract manufacturing of pharmaceutical formulations for international distribution, while the second involves marketing and distribution of sourced speciality pharmaceutical products.
The company has also expanded its international presence with products registered or under registration in countries such as Jordan, Ethiopia, Uganda, Peru, and Namibia. Its distribution network spans over 20 states in India and more than 35 countries globally. As of February 28, 2026, the company has 7 products registered internationally and 54 products under registration across 5 countries.
Why To Invest in Speciality Medicines
Growing Speciality Pharma Segment : The demand for speciality pharmaceutical products is increasing globally due to the rise in chronic diseases and complex treatments, providing long-term growth opportunities.
Strong Global Distribution Network : The company has established distribution channels in over 35 countries and across 20+ Indian states, which helps expand its market reach and revenue opportunities.
Diversified Product Portfolio : Speciality Medicines offers pharmaceutical products in multiple dosage forms such as tablets, injections, creams, inhalers, and syrups, reducing dependency on a single product category.
Healthy Financial Performance : The company reported Total Income of Rs. 58.54 crore and PAT of Rs. 8.61 crore in FY2025, showing strong profitability and growth potential.
Experienced Promoters and Management : The company is led by experienced promoters Parth B Goyani and Goyani Sumit Babubhai, who have industry knowledge and strategic experience in the pharmaceutical sector.
Explore Other Products
